Case Report of International Journal of Case Reports
Temozolamide-Associated Pancytopenia in a Patient with Glioblastoma Multiforme
Kubra Bozkurt¹ , Esra Terzı Demırsoy2, Esma Turkmen Bekmez3, Dıncer Aydın4
1Department of İnternal Medicine, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey; 2 Department of Hematology, University Health Sciences, Kocaeli Derince Training and Research Hospital , Kocaeli, Turkey; 3Department of Medical Oncology, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey; 4Department of Medical Oncology, University of Health Sciences, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor. GBM treatment is a combined modality approach involving maximum surgical resection, adjuvant postoperative radiation and adjuvant chemotherapy treatment.There is a greater risk of hematological toxicity in concurrent temozolomide and radiation therapy. We reported that pancytopenia has been developed on a 54-year old female patient with GBM after concurrently used temozolomide and radiotherapy treatment. It should be kept in mind that this side effect may develop because the risk of morbidity and mortality may be elevated. Therefore, supportive therapies should be started immediately in patients where this toxicity developed.
Keywords: Temozolomide , Glioblastoma multiforme , Pancytopenia
How to cite this article:
Kubra Bozkurt , Esra Terzı Demırsoy, Esma Turkmen Bekmez, Dıncer Aydın. Temozolamide-Associated Pancytopenia in a Patient with Glioblastoma Multiforme. International Journal of Case Reports, 2019 4:72. DOI: 10.28933/ijcr-2019-03-2106
1. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol 2016; 18:v1.
2. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293:557.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.
4. Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 2015; 314:2535.
5. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, et al. N Engl J Med. 2005;352:987–996
6. Oh J, Kutas GJ, Davey P, et al. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. Curr Oncol 2010; 17:124.
7. Clark SW, Taylor J, Wang DL, et al. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. Neurology 2013; 81:93.)
8. Neyns B, Cordera S, Joosens E, Pouratian N. Non-Hodgkin’s lymphoma in patients with glioma treated with temozolomide. J Clin Oncol 2008; 26:4518
9. Karremann M, Krämer N, Hoffmann M, et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. Eur J Cancer 2017; 81:1.
10. Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007; 9:47
11. Temozolomide induced bone marrow suppression-A single institution outcome analysis and review of the literature. Kourelis TV, Buckner JC, Gangat N, Patnaik MM. Am J Hematol. 2015;90:0. 11. Temozolomide-induced Aplastic Anemia Treated with Eltrombopag and Granulocyte Colony Stimulating Factor: A Report of a Rare Complication, Shauna L Newton, Kadra Kalamaha, and Hermina D Fernandes, Cureus. 2018; 18;10(9):e3329.
12. Temozolomide induced bone marrow suppression-A single institution outcome analysis and review of the literature. Kourelis TV, Buckner JC, Gangat N, Patnaik MM. Am J Hematol. 2015;90:0.
13. Scheinberg P, DeZern AE, Steensma DP. The American Society of Hematology Self-Assessment Program (ASH-SAP) Vol. 6. Washington, DC: American Society of Hematology; 2016. Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes; pp. 489–520.